Novel Rx
Md Yuzaiful Md Yusof Yuz6Yusof
4 months 1 week ago
#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
David Liew drdavidliew
4 months 1 week ago
LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA)
more good efficacy data, no rapidly progressive OA safety signal.
For us clinicians: impressive impact size, esp relative to alternatives.
Finally, something that works??
#EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv
Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data,
Janet Pope Janetbirdope
4 months 2 weeks ago
Is #PDE5i protective in development of
#SSc #ILD?
Maybe
444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u
#immunesuppressive use maybe or not
🤷♀️channeling bias
Reduction in new #ILD in #scleroderma
PDE5i ✅
Immunesuppression ?
@RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV
Mrinalini Dey DrMiniDey
4 months 2 weeks ago
In CareRA pooled analysis, 1 in 3 early RA pts had persistent impact (pain, fatigue, HAQ) despite improved inflammation. Female sex, longer symptom duration & low CRP were predictive. Pts more often escalated to b/tsDMARDs → risk of overtreatment?
@RheumNow #EULAR2025 #OP0330
David Liew drdavidliew
4 months 2 weeks ago
We can control inflammation in RA, but some pts still struggle with disease impact, despite improving with bDMARDs:
- lower inflamm
- higher comorbidities
Doesn’t necessarily map to fibromyalgia dx
Beyond Rx, this is the critical question
CareRA/2000
#EULAR2025 OP0330 @RheumNow https://t.co/Th3smMgtVb
David Liew drdavidliew
4 months 2 weeks ago
@RheumNow So rheumatoid nodule treatment might target some of that pathophysiology. Rituximab, abatacept, or JAKi?
And while surgery often isn’t great (plus they often grow back), definitely an option for some.
Christopher Edwards #EULAR2025 @RheumNow https://t.co/sFWnQN8uC4
Dr. John Cush RheumNow
4 months 2 weeks ago
SLE Preview: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus (SLE). Its main principle is to induce deep B-cell depletion, with the hope to reset https://t.co/OzQ05YFZfb
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. Is there a need for more medications within the same therapeutic class?
Poster Hall